Terumo sets sights on European DES (drug-eluting stent) market
This article was originally published in Clinica
Executive Summary
Japanese medtech company Terumo is venturing into the competitive drug-eluting stent (DES) market in Europe. Plans are underway to launch the firm's Biolimus A-9 eluting stent, licensed from Singapore-based Biosensors International, on the continent in the second half of the next fiscal year.